Overview

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Status:
Recruiting
Trial end date:
2028-12-16
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride
Interferon beta-1a
Interferon-beta
Interferons